• Dr. Srujan Kumar Dasyam is a Medical Gastroenterologist and has got awarded a distinction for exceptional performance in Biochemistry, 2005

• He is working as a  Consultant in Medical Gastroenterologist at KIMS Hospital,Hyderabad

• His specialization includes Medical Gastroenterologist

• He got Awarded a distinction for exceptional performance in Pharmacology and Forensic Medicine, 2007

• He got Awarded a distinction for exceptional performance in Ophthalmology, 2008

• He got Awarded a distinction for exceptional performance in Pediatrics, Obstetrics and Gynecology, 2009

• He Organized and conducted Hepatitis screening and awareness program for prisoners at central prison, Cherlapally, Hyderabad, October 2016

• He is a member of  American Society of Gastrointestinal Endoscopy

• He is a member of  Indian Society of Gastroenterology

• He is a member of  American College of Gastroenterology

• He done research on a clinical study to evaluate the sensitivity of biliary brush cytology in comparison with CT/MRI in cases of extrahepatic cholangiocarcinoma- accepted by KNR University of Health Sciences, Telangana, India.

• He done research on A clinical study of right ventricular myocardial infarction in cases of Inferior wall Myocardial Infarctionaccepted by Dr. NTR University of Health Sciences, India.

• He is the Co-Investigator for GS-US-418-3899 A Long term extension study to evaluate the safety of Filgotinib in subjects with Ulcerative Colitis. 

• He is the Co-Investigator for GS-US-419-3896 A Long term extension study to evaluate the safety of Filgotinib in subjects with Crohn's disease.

• He is the Co-Investigator for GS-US-419-3895 Combined phase 3, Double-blind, Randomized, placebo controlled studies evaluating the efficacy and safety of Filgotinib in the induction and maintenance of remission in subjects with moderately to severely active Crohn’s Disease.

• He is the Co-Investigator for GS-US-418-4279 A Randomized, Double-blind, placebo-controlled phase 2 study to evaluate the Testicular safety of Filgotinib in Adult males with moderately to severely active Inflammatory Bowel Disease.

• He is the Co-Investigator for \I6T-MC-AMAN A Phase 3

• He is the Co-Investigator for Multicenter, Randomized, Double-blind, Parallel Arm, Placebo-controlled Induction study of Mirikizumab in Conventional failed and Biological Failed patients with Moderately to severely Active Ulcerative colitis.

• He is the Co-Investigator for I6T-MC-AMBG A Phase 3, Multicenter, Randomized, Double-blind, parallel Arm, placebo-controlled Maintenance study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis. 

• He published The role of urinary spot sodium levels in assessing disease severity of chronic liver disease on admission: Journal of Clinical and Experimental Hepatology, July 2018 Srujan Kumar Dasyam, Shravan Kumar. P, Uma Devi M. DOI :10.1016/j.jceh.2018.06.405

• He published A rare case of congenital hyperbilirubinemia in pregnancy- Criggler Najjar Syndrome- II Venkatesh Pabbisetti, Srujan Kumar Dasyam, Keerthi Reddy A, Sai Krishna K. DOI: 10.1016/j.jceh.2018.06.504

• He published A case report on primary Hepatic Amyloidosis. Venkatesh Pabbisetti, Srujan Kumar Dasyam Sreedevi Sunkara, Shravan Kumar P. DOI:10.1016/j.jceh.2018.06.503

• He published A study of the clinical profile of 30 consecutive cases of poisoning presenting to a rural tertiary care center. Sujata Devi, Ashok Dasari, Srujan Kumar Dasyam , Sai Sripada Rao Perspectives in Medical Research/ January-April 2014/vol 2/issue 1(pimr.org.in)

• He presented Biliary Brush Cytology- not so Insensitive, 58th Annual Conference of Indian Society of Gastroenterology, November 2018, Bhubaneshwar.

• He presented Role of urinary sodium levels in the prognosis of decompensated liver disease, 25th Annual Scientific Meeting of Indian Association of study of Liver Diseases, August 2018, New Delhi.

• He got Awarded a distinction for exceptional performance in Biochemistry, 2005